At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
LBL-019 Injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-019 Monotherapy or Combination Anti-PD-1 Antibody in Patients With Advanced Malignant Tumors
In Brief
A Phase 2 clinical trial evaluating LBL-019 Injection and anti-PD-1 antibody injection for Advanced Malignant Tumors. Completed, enrolled 26 participants across 6 sites.
Detailed Summary
This trial is a phase I/II study, which is designed to evaluate the safety, tolerance, pharmacokinetic characteristics, receptor occupancy (RO), immunogenicity and effectiveness of LBL-019 monotherapy or combined with anti-PD-1 antibody in patients with advanced malignant tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Tumors
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartApr 2022
Primary CompletionAug 2024
TodayJul 2026
First PostedFeb 3, 2022
Enrollment StartApr 19, 2022
Primary CompletionAug 9, 2024
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 4.4 years ago
Interventions
LBL-019 Injectiondrug
initial dose-MTD
anti-PD-1 antibody injectiondrug
provide medicine base on needs